This is a Phase II study designed to estimate the efficacy of weekly low-dose PEG-Intron in pediatric patients with CNS tumors, beginning 2-10 weeks after completion of radiation therapy. The endpoint of the trial is 2-year survival compared to historical controls who have received radiation alone. To date, 22 patients have been enrolled. All patients have tolerated the PEG-Intron therapy well, with no adverse events directly attributable to the study agent. The study is enrolling 24 patients and taking an early look for efficacy. The study is ongoing.
| Steffen-Smith, Emilie A; Venzon, David J; Bent, Robyn S et al. (2012) Single- and multivoxel proton spectroscopy in pediatric patients with diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 84:774-9 |
| Hayward, Robert M; Patronas, Nicolas; Baker, Eva H et al. (2008) Inter-observer variability in the measurement of diffuse intrinsic pontine gliomas. J Neurooncol 90:57-61 |
